NCT02459301View on ClinicalTrials.gov

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 17, 2015

Primary Completion Date

November 15, 2017

Study Completion Date

November 12, 2019

Conditions
Gynecologic Cancer
Interventions
DRUG

IPH2201

Trial Locations (7)

T6G 1Z2

Cross Cancer Institute, Edmonton

V1Y 5L3

BCCA - Cancer Centre for the Southern Interior, Kelowna

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 5W9

London Regional Cancer Program, London

M5G 2M9

University Health Network, Toronto

H2L 4M1

CHUM - Hopital Notre-Dame, Montreal

Sponsors

Collaborators (1)

Innate Pharma
All Listed Sponsors
collaborator

Innate Pharma

INDUSTRY

lead

Canadian Cancer Trials Group

NETWORK